Cargando…
CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis
Several biomarkers from multiple sclerosis (MS) patients’ biological fluids have been considered to support diagnosis, predict disease course, and evaluate treatment response. In this study, we assessed the CSF concentration of selected molecules implicated in the MS pathological process. To investi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758105/ https://www.ncbi.nlm.nih.gov/pubmed/36215027 http://dx.doi.org/10.1007/s12035-022-03060-6 |
_version_ | 1784851970164523008 |
---|---|
author | Lucchini, Matteo De Arcangelis, Valeria Piro, Geny Nociti, Viviana Bianco, Assunta De Fino, Chiara Di Sante, Gabriele Ria, Francesco Calabresi, Paolo Mirabella, Massimiliano |
author_facet | Lucchini, Matteo De Arcangelis, Valeria Piro, Geny Nociti, Viviana Bianco, Assunta De Fino, Chiara Di Sante, Gabriele Ria, Francesco Calabresi, Paolo Mirabella, Massimiliano |
author_sort | Lucchini, Matteo |
collection | PubMed |
description | Several biomarkers from multiple sclerosis (MS) patients’ biological fluids have been considered to support diagnosis, predict disease course, and evaluate treatment response. In this study, we assessed the CSF concentration of selected molecules implicated in the MS pathological process. To investigate the diagnostic and prognostic significance of CSF concentration of target candidate biomarkers in both relapsing (RMS, n = 107) and progressive (PMS, n = 18) MS patients and in other inflammatory (OIND, n = 10) and non-inflammatory (ONIND, n = 15) neurological disorders. We measured the CSF concentration of APRIL, BAFF, CHI3L1, CCL-2, CXCL-8, CXCL-10, CXCL-12, CXCL-13 through a Luminex Assay. MS patients were prospectively evaluated, and clinical and radiological activity were recorded. CHI3L1 and CXCL13 CSF levels were significantly higher in both MS groups compared to control groups, while CCL2, BAFF, and APRIL concentrations were lower in RMS patients compared to PMS and OIND. Considering RMS patients with a single demyelinating event, higher concentrations of CHI3L1, CXCL10, CXCL12, and CXCL13 were recorded in patients who converted to clinically defined MS(CDMS). RMS patients in the CXCL13 and CHI3L1 high concentration group had a significantly higher risk of relapse (HR 12.61 and 4.57), MRI activity (HR 7.04 and 2.46), and of any evidence of disease activity (HR 12.13 and 2.90) during follow-up. CSF CXCL13 and CHI3L1 levels represent very good prognostic biomarkers in RMS patients, and therefore can be helpful in the treatment choice. Higher CSF concentrations of neuro-inflammatory biomarkers were associated with a higher risk of conversion to CDMS in patients with a first clinical demyelinating event. Differential CSF BAFF and APRIL levels between RMS and PMS suggest a different modulation of B-cells pathways in the different phases of the disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12035-022-03060-6. |
format | Online Article Text |
id | pubmed-9758105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-97581052022-12-18 CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis Lucchini, Matteo De Arcangelis, Valeria Piro, Geny Nociti, Viviana Bianco, Assunta De Fino, Chiara Di Sante, Gabriele Ria, Francesco Calabresi, Paolo Mirabella, Massimiliano Mol Neurobiol Article Several biomarkers from multiple sclerosis (MS) patients’ biological fluids have been considered to support diagnosis, predict disease course, and evaluate treatment response. In this study, we assessed the CSF concentration of selected molecules implicated in the MS pathological process. To investigate the diagnostic and prognostic significance of CSF concentration of target candidate biomarkers in both relapsing (RMS, n = 107) and progressive (PMS, n = 18) MS patients and in other inflammatory (OIND, n = 10) and non-inflammatory (ONIND, n = 15) neurological disorders. We measured the CSF concentration of APRIL, BAFF, CHI3L1, CCL-2, CXCL-8, CXCL-10, CXCL-12, CXCL-13 through a Luminex Assay. MS patients were prospectively evaluated, and clinical and radiological activity were recorded. CHI3L1 and CXCL13 CSF levels were significantly higher in both MS groups compared to control groups, while CCL2, BAFF, and APRIL concentrations were lower in RMS patients compared to PMS and OIND. Considering RMS patients with a single demyelinating event, higher concentrations of CHI3L1, CXCL10, CXCL12, and CXCL13 were recorded in patients who converted to clinically defined MS(CDMS). RMS patients in the CXCL13 and CHI3L1 high concentration group had a significantly higher risk of relapse (HR 12.61 and 4.57), MRI activity (HR 7.04 and 2.46), and of any evidence of disease activity (HR 12.13 and 2.90) during follow-up. CSF CXCL13 and CHI3L1 levels represent very good prognostic biomarkers in RMS patients, and therefore can be helpful in the treatment choice. Higher CSF concentrations of neuro-inflammatory biomarkers were associated with a higher risk of conversion to CDMS in patients with a first clinical demyelinating event. Differential CSF BAFF and APRIL levels between RMS and PMS suggest a different modulation of B-cells pathways in the different phases of the disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12035-022-03060-6. Springer US 2022-10-10 2023 /pmc/articles/PMC9758105/ /pubmed/36215027 http://dx.doi.org/10.1007/s12035-022-03060-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Lucchini, Matteo De Arcangelis, Valeria Piro, Geny Nociti, Viviana Bianco, Assunta De Fino, Chiara Di Sante, Gabriele Ria, Francesco Calabresi, Paolo Mirabella, Massimiliano CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis |
title | CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis |
title_full | CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis |
title_fullStr | CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis |
title_full_unstemmed | CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis |
title_short | CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis |
title_sort | csf cxcl13 and chitinase 3-like-1 levels predict disease course in relapsing multiple sclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758105/ https://www.ncbi.nlm.nih.gov/pubmed/36215027 http://dx.doi.org/10.1007/s12035-022-03060-6 |
work_keys_str_mv | AT lucchinimatteo csfcxcl13andchitinase3like1levelspredictdiseasecourseinrelapsingmultiplesclerosis AT dearcangelisvaleria csfcxcl13andchitinase3like1levelspredictdiseasecourseinrelapsingmultiplesclerosis AT pirogeny csfcxcl13andchitinase3like1levelspredictdiseasecourseinrelapsingmultiplesclerosis AT nocitiviviana csfcxcl13andchitinase3like1levelspredictdiseasecourseinrelapsingmultiplesclerosis AT biancoassunta csfcxcl13andchitinase3like1levelspredictdiseasecourseinrelapsingmultiplesclerosis AT definochiara csfcxcl13andchitinase3like1levelspredictdiseasecourseinrelapsingmultiplesclerosis AT disantegabriele csfcxcl13andchitinase3like1levelspredictdiseasecourseinrelapsingmultiplesclerosis AT riafrancesco csfcxcl13andchitinase3like1levelspredictdiseasecourseinrelapsingmultiplesclerosis AT calabresipaolo csfcxcl13andchitinase3like1levelspredictdiseasecourseinrelapsingmultiplesclerosis AT mirabellamassimiliano csfcxcl13andchitinase3like1levelspredictdiseasecourseinrelapsingmultiplesclerosis |